Search Results

Stroke Study Evaluates Predictive Value of CT Scan and Time to Recanalization

January 1, 2011—In Stroke, Mayank Goyal, MD, et al published findings from an evaluation of the association of a favorable initial noncontrast computed tomography (CT) scan and a short time to recanalization in predicting good outcomes (2011;42:93–97).

Study Analyzes Delays in Endovascular Therapy in the IMS III Trial

May 9, 2014—Findings from an evaluation of interval times from onset to reperfusion in patients undergoing endovascular therapy in the International Management of Stroke (IMS) III trial were published by Mayank Goyal, MD, et al online ahead of print in Circulation.

SNIS Lauds ESCAPE and EXTEND-IA Stroke Trials

February 11, 2015—The Society of Neurointerventional Surgery (SNIS) announced that data from the ESCAPE and EXTEND-IA clinical trials studying the treatment of stroke demonstrate that neurointerventional procedures significantly increase the number of patients who are able to live independently without major neurological disabilities.

Covidien's Solitaire FR Approved in Canada to Treat Acute Ischemic Stroke

December 13, 2012—Covidien (Mansfield, MA) announced that the company's Solitaire FR revascularization device has received regulatory approval from Health Canada.

Imperative Care’s Zoom Stroke System Will Be Evaluated for Treatment of M2 Occlusions in Investigator-Initiated RCT

April 15, 2025—Imperative Care, Inc. announced it will fund an investigator-initiated, multicenter, randomized controlled trial (RCT) comparing aspiration thrombectomy using the company’s Zoom stroke system plus best medical treatment versus best medical treatment alone.

Differences in Physician Experience and Practice Area Shown to Affect Decision-Making for Endovascular Treatment

July 24, 2019—A study presented at the Society of NeuroInterventional Surgery’s (SNIS) 16th annual meeting held July 22–25 in Miami Beach, Florida, found significant differences in decision-making for endovascular treatment when the physician’s experience with endovascular treatment (EVT) use and practice area were taken into consideration.

ESCAPE and EXTEND-IA Trials Confirm Benefits of Medtronic's Solitaire Flow Restoration Device for Stroke

February 11, 2015—Medtronic, plc announced that two studies presented at the International Stroke Conference in Nashville, Tennessee, and published online in The New England Journal of Medicine found that stent thrombectomy using the company’s Solitaire device added to the current standard of pharmaceutical treatment with intravenous tissue plasminogen activator (IV-tPA) significantly reduced disability in patients experiencing a stroke.  Both the ESCAPE (Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke) and the EXTEND-IA (Extending the Time for Thrombolysis in Emergency Neurological Deficits—Intra-Arterial) trials were investigator-initiated trials supported by an unrestricted grant from Medtronic that primarily assessed the addition of the company’s Solitaire device in conjunction with IV-tPA.

Imperative Care’s Zoom Stroke System Studied in M2 Occlusions

July 16, 2025—Imperative Care, Inc. announced findings from a subanalysis of patients with M2 occlusions enrolled in the Imperative Trial treated with the company’s Zoom stroke system.

SEER Meta-Analysis Supports Medtronic's Solitaire Stent Retriever For Acute Ischemic Stroke Treatment

February 23, 2016—Medtronic plc announced that results from the Safety and Efficacy of Solitaire Stent Thrombectomy (SEER)—Individual Patient Data Meta-Analysis of Randomized Trials were presented at the International Stroke Conference, which was held February 17 to 19 in Los Angeles, California.

Delays to Thrombectomy for Stroke Shown to Reduce Quality-of-Life and Economic Outcomes

July 24, 2018—The Society of NeuroInterventional Surgery (SNIS) announced findings from a study using a Markov model of lifetime quality-adjusted life years (QALYs) in patients treated with endovascular thrombectomy (EVT) that showed that every 10 minutes of delayed care reduced a patient’s disability-free lifetime by approximately 40 days.